Midekamycin - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Macrolides and Azalides

Included in the formulation

Macropen®

granules inwards

KRKA, dd, Novo mesto, AO

Macropen®

pills inwards

KRKA, dd, Novo mesto, AO

АТХ:

J.01.F.A.03 Midekamycin

Pharmacodynamics:

It disrupts the synthesis of microbial proteins at the level of the ribosomes, by binding to 50Sthe subunit of bacterial ribosomes, inhibits the process of translocation. It penetrates into cells and creates a high intracellular concentration.

Has a bacteriostatic effect, in high concentrations has a bactericidal effect against the causative agents of diphtheria and pertussis, as well as pneumococci.

Has a high activity against gram-positive cocci (staphylococci, streptococci).

Midekamycin also exhibits high activity against chlamydia, leptospira, treponem, mycoplasma and toxoplasma.

Pharmacokinetics:

After oral administration, the empty stomach is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 40 minutes.

The connection with plasma proteins is 80%. Penetrates into breast milk.

Metabolism in the liver with the formation of two active metabolites.

The half-life is 3 hours. Elimination with feces and kidneys (up to 10%).

Indications:

It is used to treat infectious and inflammatory diseases caused by flora sensitive to midekamycin: with pharyngitis, tonsillitis, sinusitis, otitis,infections of the urinary tract, oral cavity, skin and soft tissues.

ICD-10

I.A30-A49.A36 Diphtheria

I.A30-A49.A37 Whooping cough

I.A30-A49.A38 Scarlet fever

I.A30-A49.A46 Erys

X.J00-J06.J01 Acute Sinusitis

X.J00-J06.J02 Acute pharyngitis

X.J00-J06.J03 Acute tonsillitis

X.J00-J06.J04 Acute laryngitis and tracheitis

X.J10-J18.J15 Bacterial pneumonia, not elsewhere classified

X.J20-J22.J20 Acute bronchitis

X.J30-J39.J31 Chronic rhinitis, nasopharyngitis and pharyngitis

X.J30-J39.J32 Chronic Sinusitis

X.J30-J39.J35.0 Chronic tonsillitis

X.J30-J39.J37 Chronic laryngitis and laryngotracheitis

X.J40-J47.J42 Chronic bronchitis, unspecified

XII.L00-L08.L01 Impetigo

XII.L00-L08.L02 Abscess of skin, boil and carbuncle

XII.L00-L08.L03 Phlegmon

XII.L00-L08.L08.0 Pyoderma

XIV.N10-N16.N11 Chronic tubulointerstitial nephritis

XIV.N10-N16.N10 Acute tubulointerstitial nephritis

XIV.N30-N39.N30 Cystitis

XIV.N30-N39.N34 Urethritis and urethral syndrome

XIV.N40-N51.N41 Inflammatory diseases of the prostate

Contraindications:

Hepatic insufficiency, individual intolerance, children's age up to 3 months.

Carefully:

Hepatic insufficiency of moderate and mild severity, obstruction of bile ducts.

Pregnancy and lactation:

Recommendations for FDA - Category B. It does not have a teratogenic effect. It is used in pregnancy, it is contraindicated during lactation.

Dosing and Administration:

Use in children

Inside in the form of a suspension 2-3 times a day, single dose, depending on body weight:

less than 5 kg - 130 mg;

5-10 kg - 265 mg;

11-15 kg - 350 mg;

16-29 kg - 525 mg.

Adults

Inside 1200 mg in 2-3 divided doses.

The highest daily dose: 1200 mg.

The highest single dose: 600 mg.

Side effects:

Nausea, vomiting, diarrhea, candidiasis of the mucous membranes of the gastrointestinal tract and vagina, hyperbilirubinemia, transient increase in hepatic transaminases.

Allergic reactions.

Overdose:

Acute liver failure.

Treatment is symptomatic.

Interaction:

Reduces the excretion of warfarin and cyclosporine.

Reduces the intensity of metabolism of carbamazepine and ergot alkaloids.

Special instructions:

With prolonged treatment, liver function monitoring is necessary, especially in patients with a history of liver disease.

Instructions

Midekamycin (Midecamycinum)